ArticleFrontiers in endocrinology2025
Profiling the metabolome of adenomyosis-associated infertility patients to predict the pregnancy outcome of frozen embryo transfer.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study explores the metabolic profiles in the peripheral blood of infertile patients with adenomyosis (ADM) to identify key metabolites affecting pregnancy outcomes in these patients undergoing frozen embryo transfer (FET). Our goal is to create a metabolite-based clinical prediction model for pregnancy outcomes in adenomyosis-associated infertility. Methods: This prospective cohort study from the Reproductive Center at Peking University Third Hospital enrolled 94 infertile patients with adenomyosis and control (CTRL) patients undergoing FET. We divided these patients into four groups based on clinical pregnancy success: ADM-Success, ADM-Fail, CTRL-Success, and CTRL-Fail. We collected peripheral blood on the day of embryo transfer and analyzed metabolites using ultrahigh-performance liquid chromatography-tandem mass spectrometry. We compared metabolome differences among the four groups using bioinformatics and evaluated the diagnostic performance of metabolites for predicting pregnancy outcomes using receiver operating characteristic curves. Results: We found the metabolic differences between ADM-Success group and ADM-Fail group, and established a "5 metabolites + age" panel (5 metabolites combined with woman's age panel), which could effectively predict pregnancy outcomes of adenomyosis patients, and the area under the curve was 0.879 (P<0.001). The 5 metabolites included Androsterone, Propionic acid, Glycocholic acid, 2,6-Dihydroxypurine, Deoxycorticosterone. And this study explored the metabolic differences between adenomyosis group and control group. Conclusions: A "5 metabolites + age" panel could effectively predict pregnancy outcomes of adenomyosis patients who undergoing FET. There were notable differences in plasma metabolic profiles between adenomyosis-associated infertility and control patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.